Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:GENIL's EV-to-OCF is ranked worse than 78.93% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.145
vs IST:GENIL: 29.96
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's PE Ratio (TTM) for today is calculated as:
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's share price for today is ₺11.39.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0.152.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-OCF Related Terms
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-OCF Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
IST:GENIL vs ZTS, UTHR, VTRS: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-OCF vs Drug Manufacturers Industry
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Enterprise Value is ₺56,231 Mil.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺1,576 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a EV-to-OCF of 35.69 as of Aug. 13, 2026. This is 26% above median its historical median of 28.24. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #794 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 78.9%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EV-to-OCF too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EV-to-OCF of 35.69 is 26% above median its 10-year median of 28.24. The Drug Manufacturers industry median EV-to-OCF is 11.15. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 35.69 is 220.2% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #794 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #794 out of 1006 companies for EV-to-OCF. This places Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the lower half of its industry. The industry median EV-to-OCF is 11.15. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 35.69 is 220.2% above this benchmark. While the company's 10-year median is 28.24 vs. the industry median of 11.15, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.15, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EV-to-OCF of 35.69 is 220.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EV-to-OCF is 35.69, which is 26% above median its own 10-year median of 28.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺8.27, compared to a current price of ₺11.39 — trading 37.7% above its estimated fair value. The current EV-to-OCF is 35.69, which is 26% above median its 10-year median of 28.24 and 220.2% above the Drug Manufacturers industry median of 11.15. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current EV-to-OCF is 35.69 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺11.39 is trading 37.7% above its estimated GF Value™ of ₺8.27.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Significantly Overvalued.
Key valuation signals for IST:GENIL:
EV-to-OCF: 35.69 (26% above median its 10-year median of 28.24)
GF Value™: ₺8.27 vs. price of ₺11.39 (37.7% above fair value)
Industry Position: 220.2% above the Drug Manufacturers median (#794 of 1006)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
85GF Score
Get the complete analysis for IST:GENIL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
